Iterum Therapeutics

OverviewSuggest Edit

Iterum Therapeutics is a clinical-stage pharmaceutical company which aims to treat serious infections resulting from multi-drug resistant bacteria. It is engaged in developing differentiated anti-infectives. The Company offers an oral and intravenous antibiotic for the treatment of Gram-negative multi-drug resistant infections.
TypePrivate
Founded2015
HQDublin, IE
Websiteiterumtx.com

Latest Updates

Employees (est.) (Jan 2021)30(-11%)
Cybersecurity ratingAMore

Key People/Management at Iterum Therapeutics

Corey N. Fishman

Corey N. Fishman

CEO & Director
Mark Chin

Mark Chin

Director
Brenton K. Ahrens

Brenton K. Ahrens

Interim Chairman
Michael Dunne

Michael Dunne

Director
Judith M. Matthews

Judith M. Matthews

CFO
Patrick J. Heron

Patrick J. Heron

Director
Show more

Iterum Therapeutics Office Locations

Iterum Therapeutics has offices in Dublin, Chicago and Old Saybrook
Dublin, IE (HQ)
4th Floor, Block 2, Harcourt Centre, Harcourt Street, Dublin 2
Chicago, IL, US
200 South Wacker Drive, 200 S Wacker Dr #2550
Old Saybrook, CT, US
20 Research Pkwy
Show all (3)

Iterum Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Iterum Therapeutics total Funding

$105 m

Iterum Therapeutics latest funding size

$65 m

Time since last funding

4 years ago

Iterum Therapeutics investors

Iterum Therapeutics's latest funding round in May 2017 was reported to be $65 m. In total, Iterum Therapeutics has raised $105 m
Show all financial metrics

Iterum Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Iterum Therapeutics Online and Social Media Presence

Embed Graph

Iterum Therapeutics News and Updates

Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities--

Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020

Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority

Bilayer tablet patent application could provide U.S. patent coverage for Iterum’s commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent coverage for Iterum’s commercial formulation through 2039, if granted

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

--First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved-- --Potential Approval Q3 2021 with Priority Review--

Iterum Therapeutics Reports Third Quarter 2020 Financial Results

NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020

Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections

--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug r…
Show more

Iterum Therapeutics Blogs

Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering

DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital s…

UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antib…

Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiot…

Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi…

Iterum Therapeutics Announces Revised Results of Rights Offering

DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi…

Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Offering

DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, …
Show more

Iterum Therapeutics Frequently Asked Questions

  • When was Iterum Therapeutics founded?

    Iterum Therapeutics was founded in 2015.

  • Who are Iterum Therapeutics key executives?

    Iterum Therapeutics's key executives are Corey N. Fishman, Mark Chin and Brenton K. Ahrens.

  • How many employees does Iterum Therapeutics have?

    Iterum Therapeutics has 30 employees.

  • Who are Iterum Therapeutics competitors?

    Competitors of Iterum Therapeutics include Pharmo Institute, Hyloris Pharmaceuticals and ReCept Pharmacy.

  • Where is Iterum Therapeutics headquarters?

    Iterum Therapeutics headquarters is located at 4th Floor, Block 2, Harcourt Centre, Harcourt Street, Dublin 2, Dublin.

  • Where are Iterum Therapeutics offices?

    Iterum Therapeutics has offices in Dublin, Chicago and Old Saybrook.

  • How many offices does Iterum Therapeutics have?

    Iterum Therapeutics has 3 offices.